Hepatitis B vaccines: Protective efficacy and therapeutic potential
Hepatitis B vaccines: Protective efficacy and therapeutic potential
复制标题
DOI：
10.1016/j.patbio.2010.01.006
复制
发表时间：
2010-08-01
影响因子：
--
通讯作者：
Tiollais, P.
中科院分区：
文献类型：
--
作者：
Michel, M. -L.;Tiollais, P.
在世界范围内，有20亿人曾感染过B型肝炎病毒，3.7亿人患有慢性感染，每年约有100万人死于HBV相关的肝病，其中肝癌是最终阶段。接种疫苗是降低全球B型肝炎发病率最有效的措施，并且B型肝炎疫苗现已上市超过20年。第一种B型肝炎疫苗是从纯化自无症状B型肝炎病毒携带者血浆的灭活B型肝炎表面抗原颗粒制备的。对B型肝炎病毒的结构和基因组组织的了解导致了第一个DNA重组疫苗的开发。在预防肝细胞癌的发展中，B型肝炎病毒疫苗被认为是第一种可用的癌症疫苗HBV疫苗最近作为治疗性疫苗发挥了新的作用，试图治愈或控制持续感染个体的B型肝炎病毒感染（C）2010 Elsevier Masson SAS保留所有权利。
Worldwide, two billion people have at some time been infected by hepatitis B virus, 370 millions suffer from chronic infection and around one million die each year from HBV-related liver diseases of which liver cancer is the ultimate stage. Vaccination is the measure that is most effective in reducing the global incidence of hepatitis B and hepatitis B vaccines have now been available for over 20 years The first hepatitis B vaccine was prepared from inactivated hepatitis B surface antigen particles purified from plasma of asymptomatic carriers of hepatitis B virus. Knowledge of the structure and genomic organization of hepatitis B virus has led to development of the first DNA recombinant vaccine. In preventing hepatocellular carcinoma development, hepatitis B virus vaccines are considered as the first available cancer vaccine HBV vaccines have recently taken on a new role as therapeutic vaccines as an attempt to cure or to control hepatitis B virus infection in persistently infected individuals (C) 2010 Elsevier Masson SAS All rights reserved.